Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Service; Medical Device; Manufacturing; Consumer Products
Companies Profiled:
Abbott; Selvita S.A.; Astellas; AstraZeneca; Baxter International; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Merck Serono; Onyx Pharmaceuticals; Sanofi-aventis; Takeda Pharmaceuticals; Gilead Sciences; MedImmune; Monogram Biosciences; Exelixis
Table of Contents
Executive Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Key Findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
Total Oncology-GSM Investment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Investment Breakout for Activities within Marketing, Market Intelligence & Advocacy Budgets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Investment Allocation by Product Development Phase . . . . . . . . . . . . . . . . . . . . 26
Investment Normalized by Number of Programs, Products & Labels . . . . . . . . . 32
Investment Normalized by Oncology Sales Revenue . . . . . . . . . . . . . . . . . . . . . . 38
Comparative FTE Levels & Staffing Practices . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Structure of Oncology-GSM Organizations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
Leadership Roles in Key Oncology-GSM Activities . . . . . . . . . . . . . . . . . . . . . . . . . 56
Oncology-GSM Investment Trends, Next Two Years . . . . . . . . . . . . . . . . . . . . . . . . 65
Success Factors & Pitfalls in Oncology-GSM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
Definitions & Abbreviations Used in Survey . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73